Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Financial Performance - Keros Therapeutics reported a quarterly loss of $1.14 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.93, representing an earnings surprise of -22.58% [1] - The company posted revenues of $3.04 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 97.11$0.14 million in the same quarter last year [2] - Over the last four quarters, Keros Therapeutics has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during this period [2] Stock Performance - Keros Therapeutics shares have declined approximately 31.1% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.33 on revenues of$0.1 million, while for the current fiscal year, it is -$4.87 on revenues of$90.68 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Keros Therapeutics' stock performance [5][6]